The U.S. trade deficit remains on par to crack $1 trillion again. Meanwhile, a soft decoupling from China can be seen in the latest trade data.
The China tariffs, enacted by Lighthizer under Trump, are under review later this year. Will they stay or will they go? Lighthizer thinks they should stay…with more tariffs added.
The House Select Committee on the CCP published a preliminary report on the use of forced labor in Shein and Temu supply chains. Many Americans are investors.
Don’t blame the China tariffs on inflation. Supply chain snafus were a much bigger deal, a Federal Reserve report says.
At National Press Club, Katherine Tai talks about supply chain issues, what ‘de-risking’ from China might look like, and how USTR thinks about it.
A Chinese cancer drug maker that has not been inspected by the FDA since 2018 is selling chemotherapy drugs to the U.S. due to shortages. When will the U.S. meet its critical medication needs?
The House Financial Services Committee says American consumers are helped by a strong dollar, which lowers the price of imports to the tune of up to $45 billion per year in savings. In a $23 trillion economy, is an overvalued dollar really worth it?
China as a source for American imports is on the wane thanks to tariffs, other business risks. But strong dollar keeps imports booming.
The balance between scarcity and supply favors supply, even if that means importing drugs from labs the FDA has not inspected.
Meet the Chinese companies banned by Commerce and the State Department, but still able to attract billions from Wall Street fund managers.